Nautilus Biotechnology Q3 revenue beats

Overview

• US proteomics platform developer's Q3 revenue beat analyst expectations

• Company's Q3 net loss widened from a year earlier

• Operating expenses increased 10% due to higher lab, professional services and personnel costs

Outlook

• Nautilus expects Voyager platform instrument availability in mid-2027

• Company plans to deliver twenty proteoform assays through mid-2028

• Nautilus expects up to $6 mln in SEEDS consortium funding for Voyager platform deployment

Result Drivers

• GRANT AND SERVICE REVENUE - Q3 revenue was mainly from a grant awarded by The Michael J. Fox Foundation and sales of services under the Iterative Mapping Early Access Program

• HIGHER OPERATING COSTS - Increased lab, professional services, and personnel expenses drove up operating costs in Q3

• RESEARCH PROGRESS - Co published peer-reviewed research demonstrating potential for new biomarkers and drug targets

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for Nautilus Biotechnology, Inc. is $4.00, about 63.9% above its October 26 closing price of $2.44

Reuters Recommended Reads

• Oct 26 - Johnson & Johnson's prostate cancer drug shrinks tumors in early-stage trial

• Oct 24 - Amgen drug combined with immunotherapy extends survival in lung cancer trial

• Oct 26 - Acumen Pharmaceuticals posts smaller than expected Q3 loss

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)